Concert of regulators to switch on LEE expression in enterohemorrhagic Escherichia coli O157:H7: interplay between Ler, GrlA, HNS and RpoS

International Journal of Medical Microbiology : IJMM
Maria-Halima LaaberkiFrancis Repoila

Abstract

Enterohemorrhagic (EHEC) and enteropathogenic (EPEC) Escherichia coli strains carry a pathogenicity island termed locus of enterocyte effacement (LEE) responsible for attaching and effacing lesions on epithelial cells. The expression of LEE varies among isolates and is dependent on environmental cues. In the EHEC O157:H7 Sakaï isolate (RIMD-0509952 strain), we found that the non-coding RNA, DsrA, activates the expression of the LEE. This activation requires RpoS, the stress sigma factor. The DsrA/RpoS regulatory pathway mediates its positive effect by stimulating the transcription of ler, a positive regulatory gene encoded by the LEE. A second regulatory pathway, repressed by HNS, is also able to activate the transcription of ler and requires GrlA, another LEE-encoded regulator. Both regulatory pathways, DsrA/RpoS and HNS/GrlA, affect the activity of the ler distal promoter and require the Ler protein to be functional. Our data demonstrate that the LEE expression can be turned on by at least two separate pathways acting on the transcription of ler.

References

Feb 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·T K McDanielJ B Kaper
Oct 15, 1998·Proceedings of the National Academy of Sciences of the United States of America·N MajdalaniS Gottesman
Jun 1, 2000·Proceedings of the National Academy of Sciences of the United States of America·K A Datsenko, B L Wanner
Aug 26, 2000·Journal of Bacteriology·E Schlosser-SilvermanS Altuvia
Dec 15, 2000·Molecular Microbiology·V SperandioJ B Kaper
Jul 11, 2001·Genes & Development·K M WassarmanS Gottesman
Sep 5, 2002·Microbiology and Molecular Biology Reviews : MMBR·Regine Hengge-Aronis
Sep 6, 2002·Microbiology·Tatiana UmanskiDevorah Friedberg
Dec 24, 2002·Infection and Immunity·Kenneth R HaackJay L Mellies
Nov 5, 2003·Journal of Bacteriology·F Repoila, S Gottesman
Feb 28, 2004·Proceedings of the National Academy of Sciences of the United States of America·Wanyin DengB Brett Finlay
Apr 22, 2004·Nature Reviews. Microbiology·Charles J Dorman
Aug 20, 2004·Journal of Bacteriology·Thea KingThomas Ferenci
Sep 3, 2004·Journal of Bacteriology·Richard A LeaseMarlene Belfort
Oct 19, 2004·Annual Review of Microbiology·Susan Gottesman
Mar 23, 2005·Lancet·Phillip I TarrWayne L Chandler
May 24, 2005·Infection and Immunity·James B Kaper, Vanessa Sperandio

❮ Previous
Next ❯

Citations

Apr 17, 2007·Nature Structural & Molecular Biology·Emeline BouffartiguesSylvie Rimsky
Nov 23, 2010·The Journal of Antimicrobial Chemotherapy·Kunihiko NishinoAkihito Yamaguchi
Nov 5, 2008·Infection and Immunity·Tao DongHerb E Schellhorn
Dec 2, 2009·Infection and Immunity·Tao Dong, Herb E Schellhorn
Jun 26, 2007·Journal of Bacteriology·Alfredo G TorresYgnacio Martínez-Laguna
Oct 11, 2011·Journal of Bacteriology·Melissa M KendallVanessa Sperandio
May 9, 2014·Future Microbiology·Herb E Schellhorn
Apr 16, 2010·Canadian Journal of Physiology and Pharmacology·Julie-Anna M BenjaminEric Massé
Jul 3, 2009·Molecular Microbiology·Anne-Marie Hansen, James B Kaper
Sep 8, 2011·Molecular Microbiology·Víctor H BustamanteJosé L Puente
Jun 12, 2016·Microbial Pathogenesis·Yiquan ZhangFengjun Sun
Oct 19, 2007·Nature·Mark J Pallen, Brendan W Wren
Aug 15, 2014·The Journal of Biological Chemistry·Chun-Han HoAndrew H-J Wang
Sep 8, 2018·Frontiers in Microbiology·Nathan Horn, Arun K Bhunia

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.